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PURPOSE. To investigate the role of Y-27632, a specific inhibitor
of Rho-associated protein kinase (ROCK) in regulating human
Tenon fibroblast (HTF) activities including proliferation, adhe-
sion, contraction, migratory response, and myofibroblast trans-
differentiation. Effects of Y-27632 on prevention of postoper-
ative scar formation were also examined in a rabbit model of
glaucoma filtration surgery.
METHODS. After treatment of HTFs with Y-27632, cell toxicity,
proliferation, migration, adhesion, and contraction were stud-
ied. The cytoskeleton and -smooth muscle actin (-SMA)
expression were examined via immunohistochemistry. In vivo
studies in Japanese white rabbits consisted of a full-thickness
sclerostomy followed in the 7-day postoperative period by
topical application of Y-27632. Intraocular pressure, morpho-
logic changes in bleb features, and histology of surgical sites
were evaluated.
RESULTS. Y-27632 had no direct toxicity or significant effects on
cell proliferation of HTF. The cell adhesion assay showed that
Y-27632 promoted adhesiveness to both fibronectin and colla-
gen type I. Use of Y-27632 significantly inhibited collagen gel
contraction and -SMA expression in HTFs. Y-27632 also in-
creased HTF motility. In vivo, Y-27632 inhibited wound heal-
ing and fibroproliferation after filtration surgery and signifi-
cantly improved surgical outcome compared with the vehicle.
Histologic examination revealed that blebs in the Y-27632-
treated group differed from those in the vehicle-treated group
in that they lacked significant collagen deposition in the scler-
ostomy area.
CONCLUSIONS. Y-27632 had profound effects on activities of
HTFs and was effective in preventing fibroproliferation and
scar formation in a rabbit model of glaucoma surgery. A ROCK
inhibitor may be an effective anti-scarring agent after glaucoma
filtering surgery. (Invest Ophthalmol Vis Sci. 2007;48:
5549–5557) DOI:10.1167/iovs.07-0878
The main cause of failure of glaucoma filtration surgery ispostoperative scarring in the filtering bleb. Perioperative
administration of antimetabolites such as 5-fluorouracil and
mitomycin C (MMC) is effective in limiting the scarring pro-
cess. However, use of these antiproliferative agents is accom-
panied by severe side effects.1 Fibroblasts from the subcon-
junctival space play a key role in the scarring process. Several
agents, such as antibody against transforming growth factor
(TGF)-2,2 alkylphosphocholines,3 and p38 inhibitors,4 are re-
portedly potential alternative antiscarring therapeutic sub-
stances, in that they can regulate activities of fibroblasts, but
they are not yet available for routine clinical use.
Fibroblasts generate a contractile force, which is essential
for their role in the postoperative scarring process.5 In addi-
tion, transdifferentiation of fibroblasts into myofibroblasts is a
crucial step in wound healing and scar formation,6 which is
associated with expression of -smooth muscle actin (-SMA).7
Enhanced -SMA expression indicates the presence of acti-
vated fibroblasts with increased synthesis of extracellular ma-
trix (ECM) proteins, growth factors, and integrins.4,8
The Rho subfamily of small GTPases (including Rho and
Rac) has critical functions in regulation of actomyosin cytoskel-
etal organization, cell adhesion, and cell motility.9–12 The cy-
toskeleton is regarded as a primary target of growth factor
action and mediates several cell responses to the ECM.10,13,14
ROCK I, one of the putative target molecules of Rho, has been
identified as a Rho effector.15 ROCKs are important for regu-
lating focal adhesions and stress fiber formation in cultured
fibroblasts and epithelial cells.16,17 We have reported that a
specific inhibitor of ROCK I, Y-27632, causes significantly
reduced intraocular pressure (IOP) in rabbits and altered cell
shape and the actin cytoskeleton of cultured human trabecular
meshwork (TM) cells.18 We have also demonstrated that
Y-27632 has profound effects on TM cell activities.19 In addi-
tion, Rho has been implicated in pathologic wound healing.20
We hypothesize that Rho plays an important role in modula-
tion of cytoskeletal dynamics in human Tenon fibroblasts (HTFs)
and thereby influences HTF activities. Although some research
has implicated TGF--mediated growth factors in modification of
HTF activities,4,21 the effects of ROCK inhibitors on cytoskeletal
organization, proliferation, and transdifferentiation into myofibro-
blasts in HTFs have not been fully explored. In particular, the
involvement of the Rho signaling pathways in mediating such
effects in animal models is unknown. Therefore, in this study we
used Y-27632 to test its ability to inhibit proliferation, migration,
and contraction of HTFs without toxicity. We also investigated its
effect on preventing fibroproliferation and scar formation in a
rabbit model of glaucoma surgery. These results suggest that this
ROCK inhibitor may effectively prevent postoperative filtration
bleb failure in glaucoma surgery.
MATERIALS AND METHODS
Culture of HTFs
Small Tenon biopsy specimens were obtained during standard cataract
surgery after selected patients had received comprehensive informa-
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tion and provided written consent for the procedure. The protocol was
approved by the Institutional Review Board at Kyoto University in
compliance with tenets of the Declaration of Helsinki. Primary HTFs
obtained from expansion cultures of the Tenon explants were propa-
gated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum and antibiotics. Cells were
maintained in the logarithmic growth phase, and cells from passages 3
to 6 were used in all experiments, which were performed at least three
times with similar results.
Trypan Blue Exclusion Test
The cytotoxicity of Y-27632 was evaluated via a trypan blue exclusion
test. Viable cells were counted in vitro according to a previously
described method.19,22 Briefly, 5  105 HTFs were plated and grown
for 24 hours, then treated with or without Y-27632 (1, 10, or 100 M)
for 24 hours. After trypan blue treatment, stained, and unstained cells
were counted by using a hematocytometer. The percentage of cell
viability was calculated according to the following formula: % cell
viability  (viable cell count/total cell count)  100. Five independent
experiments were performed.
Cell Proliferation Assay
Proliferation of cultured HTFs was measured by use of the commer-
cially available MTT (3-(4,5-dimethyl-2-thiazyl)-2, 5-diphenyl-2H-tetrazo-
lium bromide) cell proliferation kit (Nacalai Tesque, Kyoto, Japan),
according to the manufacturer’s instructions. Cells were plated at a
density of 1  104 cells per well in 96-well plates and were allowed to
adhere for 24 hours. After cultures were washed with phosphate-
buffered saline (PBS), they were incubated with or without Y-27632 (1,
10, or 100 M) for 72 hours and then treated with 5 mg/mL MTT for
4 hours at 37°C. The relative active number of cells was determined by
an automated plate reader (Bio-Rad, Hercules, CA).
Cell Adhesion Assay
The cell adhesion assay was performed as previously described.19,23
Wells in 96-well plates were coated overnight with 10 g/mL fibronec-
tin (Sigma-Aldrich-Aldrich, St. Louis, MO) or 0.5 g/mL collagen type I
(Calbiochem, San Diego, CA) at 4°C. Remaining binding sites were
blocked by 0.1% bovine serum albumin (BSA) in PBS. HTFs in culture
medium containing 2 mg/mL BSA with or without Y-27632 (1, 10, or
100 M) were loaded onto coated wells at 4  104 cells per well. After
incubation for 60 minutes, unattached cells were removed and washed
with PBS. Then, 100 L of calcein-AM solution (Calbiochem) was
added to each well and incubated for 60 minutes. The relative remain-
ing number of cells was determined by an automated plate reader
(Bio-Rad).
Collagen Gel Contraction Assay
This assay was performed as previously described,19,24,25 with minor
modifications. Briefly, HTFs were trypsinized and resuspended in cul-
ture medium at a density of 2.2  106 cells/mL, with or without
Y-27632 (1, 10, or 100 M). Collagen type I (Nitta Gelatin, Osaka,
Japan), 10  DMEM, reconstitution buffer (Nitta Gelatin), HTF cell
suspension, and water were mixed in an ice bath at a ratio of 7:1:1:1.
Aliquots (0.5 mL) of the resultant mixture were added to each well of
1% BSA-coated 24-well clusters and collagen gel formation was in-
duced. DMEM (0.5 mL), with or without Y-27632 (1, 10, or 100 M),
was then placed on top of the collagen gels. After 1 hour of incubation,
gels were freed from the walls of the culture wells, and diameters of
the gels were scanned into a computer and measured every 24 hours
for 4 days.
Immunohistochemistry
HTFs were plated on glass coverslips, cultured overnight, and then
serum starved for 24 hours. Then, 10 M lysophospholipid acid (LPA;
Sigma-Aldrich) was added for 10 minutes, after which it was incubated
with Y-27632 (1, 10, or 100 M) for 30 minutes. After this exposure,
the cells were fixed in 2% paraformaldehyde-PBS for 15 minutes and
then blocked in 2% BSA for 30 minutes. Coverslips were incubated
with anti-vinculin antibody (Sigma-Aldrich) or -SMA antibody (Dako
Japan, Kyoto, Japan) for 30 minutes. Rhodamine-phalloidin (Invitro-
gen-Molecular Probes, Eugene, OR) was used to counterstain the F-
actin cytoskeleton. Samples were washed with PBS and incubated with
FITC-conjugated secondary antibody (Chemicon, Temecula, CA) for 30
minutes. After they were washed, the cells were mounted in antifade
medium and observed via the fluorescence microscope (model IX71;
Olympus, Tokyo, Japan). Immunohistochemistry with rabbit speci-
mens used the same routine procedure.
Measurement of Cell Motility Activities
HTFs were grown to confluence in 100-mm tissue culture dishes.
Three or four sites in each dish were scraped with a yellow plastic
pipette tip to remove the confluent cells and create a linear line.
Medium was replaced with fresh medium, with or without Y-27632 (1,
10, or 100 M). After incubation at 37°C for 9 hours, the movement of
cells into the wound area was photographed by a digital microscope
camera (Olympus) and analyzed via computer software (Olympus).
The shortest distance between the edges of migrated HTFs (including
protrusions) from both sides was measured, as previously de-
scribed.19,26
Animals and Sclerostomy Protocol
Twelve female Japanese White rabbits (Pasteurella free, each 2.0 to
2.4 kg, 12 to 14 weeks old; SRC Japan, Osaka, Japan) were used.
Experiments were conducted according to guidelines of the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research
and approved by the Animal Use Committee at Kyoto University. All
investigations involving rabbits, including surgery, IOP measurements,
bleb scoring, and determination of histologic features, were conducted
in a blinded manner.
Rabbits were anesthetized with an intramuscular injection of ket-
amine hydrochloride (5 mg/kg body weight), and xylazine hydrochlo-
ride (5 mg/kg body weight). A limbus-based flap of the conjunctiva and
the Tenon capsule was made at a distance of 5 mm from the limbus in
the superior nasal quadrant of the right eye. A sclerostomy was per-
formed, and a fistula was constructed toward the anterior chamber.
The conjunctiva was closed with three 8-0 polyglactin 910 sutures.
After bleb formation was tested, topical Y-27632 or PBS (12 L of eye
drops of 10 mM Y-27632 or the same amount of PBS) was applied to
the eye. After surgery, 1 cm of 3 mg/g ofloxacin ointment was applied
to the eye. Topical Y-27632 or PBS was applied for 7 postoperative
days.
Clinical Evaluation of Postoperative Y-27632
Effects in a Rabbit Model of Glaucoma
Filtration Surgery
Glaucoma Filtration Surgery. Baseline observations were
obtained before surgery. The IOP of the rabbit eye was measured
during topical instillation of anesthetic before and after surgery by
using an applanation tonometer (Tonovet; Tiolat, Helsinki, Finland).
IOP was monitored daily for 7 postoperative days, with values obtained
at the same time each day. Blebs were examined via a slit lamp and
were graded as previously described by Perkins et al.,27 according to a
qualitative scale of 1 to 4, reflecting increasing bleb height and size
as follows: 1, minimal height, conjunctiva thickening, no microcysts;
2, microcysts present; 3, elevated bleb covering 2 to 3 clock hours
of the eye; and 4, greatly elevated bleb covering more than 4 clock
hours. A score of 0 indicated no observable bleb. Bleb failure was
defined as the appearance of a flat, vascularized, scarred bleb in the
presence of a deep anterior chamber.
Histologic Evaluation. For this study, rabbits were killed hu-
manely 7 days after surgery. An incision was made 90° away from the
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surgical site, and the whole globe was fixed in 4% paraformaldehyde in
PBS for 48 hours at 4°C and was then embedded in medium (Tissue-
Tek; Sakura Finetechnical, Tokyo, Japan). Serial sections were cut
through the sclerostomy site. Approximately every fifth section was
stained with standard hematoxylin-eosin (HE), elastica van Gieson
(EVG; for collagen), or -SMA. The extent of fibroproliferation and scar
formation in sections was evaluated in a blinded manner.
Statistical Analysis
Data are presented as the mean  SEM. Statistical comparisons of
multiple groups used one-way or two-way repeated-measures anal-
ysis of variance (ANOVA) followed by the Bonferroni/Dunn post
hoc test. Comparisons of two groups used Student’s t-test with
Bonferroni correction. Differences were considered statistically sig-
nificant at P  0.05.
RESULTS
Toxicology of Y-27632: Effects on HTFs
The result of the trypan blue exclusion test showed that the
percentage of living HTFs was 96.4%  0.3% in control cul-
tures without Y-27632 treatment. In experimental cultures
treated with various concentrations of Y-27632, percentages of
living cells were 96.7%  0.4%, 97.3%  0.5%, and 96.5  0.4
for 1, 10, and 100 M Y-27632, respectively. These values were
not significantly different from the control value.
Cell proliferation was measured by the MTT assay. The assay
is based on measuring the intracellular formazan spectropho-
tometrically which is facilitated by active cells. The optical
absorbance of Y-27632-treated cells were 0.66  0.02, 0.66 
0.02, and 0.67  0.01 for 1, 10, and 100 M Y-27632 respec-
tively, while that of control cells was 0.67  0.03. The MTT
assay revealed no significant differences between Y-27632-
treated HTFs and control samples. This inhibitor thus displayed
little toxicity and had no effect on proliferative activity of HTFs.
Influence of Y-27632 on Adhesion of HTFs to
the ECM
Compared with controls, greater numbers of Y-27632-treated
HTFs adhered to fibronectin and collagen type I, with adhesion
to both fibronectin and collagen showing a Y-27632 concen-
tration-dependent effect (Fig. 1). Results were statistically sig-
nificant for both fibronectin (at 10 M) and collagen type I (at
100 M).
Effects of Y-27632 on the Cytoskeleton and on
-SMA Expression
In an immunohistochemical study, LPA treatment induced as-
sembly of actin stress fibers and increased the number of focal
adhesions in HTFs. Addition of Y-27632 prevented this assem-
bly and focal adhesion expression (Figs. 2A, 2B). Addition of
LPA, however, caused redistribution of focal adhesions in the
cell periphery. (Fig. 2B).
HTFs were stimulated with LPA in the presence of 10 M
Y-27632 or vehicle control. Although untreated serum-starved
cells showed weak -SMA staining, LPA treatment induced
assembly of -SMA-positive stress fibers in approximately 50%
of the cells, and addition of Y-27632 prevented these LPA-
induced effects (Fig. 2C).
Gel Contraction Assay
Compared with controls, Y-27632 caused significant concen-
tration-dependent inhibition of HTF-mediated collagen gel con-
traction in the presence of serum (Fig. 3A). At 48 hours after
plating and incubation without Y-27632, the original diameter
of the gels (16 mm) changed to 5.5  0.2 mm (n  4).
However, with addition of 1, 10, or 100 M Y-27632, collagen
gel diameters at the same time point measured 4.4  0.4, 1.9 
0.2, and 0.4  0.2 mm, respectively (Fig. 3B). Experiments at
72 and 96 hours produced similar results. Results were statis-
tically significant, and dose dependency was evident (P 
0.001).
HTF Cell Motility Activities
At 9 hours after the scraping, the distance between the edges
of the exposed regions was 71.7%  4.4%, 51.2%  3.6%,
24.9%  3.0%, 7.6  2.8% respectively, with Y-27632 at 0
(control), 1, 10, and 100 M (Fig. 4). The increase in Y-27632-
induced wound healing was significant and depended on con-
centration.
Effects of Y-27632 on Filtration Blebs
Topical instillation of Y-27632 significantly improved the re-
sults of glaucoma filtration surgery in this rabbit model and
prolonged bleb survival compared with vehicle-treated control
animals. Figure 5A shows the typical appearance of the blebs
during the 7 postoperative days. Slit lamp examination showed
that the treatment with Y-27632 was associated with elevated,
diffuse blebs with mild conjunctival injection rather than the
flat, scarred, vascularized blebs in the controls. In the vehicle-
treated controls, vascularization in the conjunctiva was signif-
icant. Although no significant differences in anterior chamber
depth or anterior chamber inflammation were observed be-
tween Y-27632-treated and control groups, postoperative IOP
was significantly lower in the Y-27632-treated group (Fig. 5B).
No significant postoperative changes in pupil dilation or cor-
nea were observed in both groups. Analysis of bleb scores
revealed significant differences between the Y-27632-treated
and vehicle-treated control groups (Fig. 5C).
Effects of Y-27632 on Histologic Characteristics of
Eyes in a Rabbit Model of Glaucoma
Filtration Surgery
Surgical sites were examined 7 days after the surgery and
stained with HE, EVG, or -SMA. HE stain of vehicle-treated
eyes exhibited nearly complete scarring over the sclerostomy
site (Fig. 6A), including evidence of new collagen deposition in
the scleral gap and bleb area, as shown by EVG stain (Fig. 6C).
FIGURE 1. Effect of Y-27632 on adhesion of HTFs. To elucidate inter-
actions between cultured HTFs and ECM components, adhesion of
HTFs to fibronectin-coated or collagen type I–coated dishes was inves-
tigated. The cells were plated on dishes coated with fibronectin (10
g/mL) or collagen type I (0.5 g/mL) and were allowed to adhere in
the absence or presence of 10 or 100 M Y-27632 for 60 minutes.
Adherence was measured by means of the calcein-AM assay. The
relative remaining number of cells was determined based on optical
absorbance of fluorescence with an emission wavelength of 520 nm
measured by an automated plate reader. Data are expressed as the
mean  SEM (n  6). *P  0.05 versus control.
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In contrast, HE stain showed that postoperative scar formation
at day 7 was significantly reduced by Y-27632 treatment (Fig.
6B). EVG stain showed that eyes treated with Y-27632 had bleb
cavities of moderate size and evidence of minimal deposition of
new collagen in the sclera (Fig. 6D). As judged by EVG with
higher magnification, both the conjunctiva and the subcon-
junctival scar (Fig. 6E) and the area around the failed bleb (Fig.
6G) in the vehicle-treated group consisted of dense collagen
fibers and scar tissue. In contrast, the surviving Y-27632-treated
bleb showed a much looser architecture with a visible con-
junctiva (Fig. 6F) and bleb formation with fewer collagen
deposits (Fig. 6H). The sclerostomy area in the vehicle-treated
eye consisted of densely packed collagen (Fig. 6I), whereas the
site in the Y-27632-treated group differed and showed loose
cell infiltration without significant collagen deposition (Fig. 6J).
At the microscopic level, no significant changes in the trabec-
ular meshwork were observed after Y-27632-treatment com-
pared with the vehicle-treated group.
Immunohistochemical staining of blebs on postoperative day
7 demonstrated reduced expression of -SMA after Y-27632 treat-
ment (Fig. 6K) compared with the control (Fig. 6L).
DISCUSSION
Scarring is a major reason for failure of filtration surgery.
Several studies showed that subconjunctival scarring of the
FIGURE 2. Effect of Y-27632 on the
cytoskeleton and on -SMA expres-
sion. (A) Distribution of F-actin in
HTFs. Serum-starved HTFs were incu-
bated with 10 M LPA for 10 minutes
and were then incubated without
(control, 0 M) or with 1, 10, or 100
M Y-27632 for 30 minutes. Experi-
ments repeated three times yielded
similar results. (B) Distribution of F-
actin and vinculin in HTFs. Serum-
starved HTFs were stimulated with
10 M LPA for 10 minutes and were
then incubated with 10 M Y-27632
for 30 minutes. LPA induced assem-
bly of actin stress fibers (B, white
arrows) and redistribution of focal
adhesions in the cell periphery (B,
white arrowheads), and Y-27632
prevented these effects. Right:
merged images. (C) Distribution of
F-actin and -SMA in HTFs. -SMA
expression is a hallmark of myofibro-
blast generation and the cells’ fibro-
genic reaction. The cells were stimu-
lated with LPA in the presence of 10
M Y-27632. LPA treatment induced
assembly of -SMA-positive stress fi-
bers (C, white arrows). Y-27632 pre-
vented LPA-induced expression of
-SMA and its incorporation into ac-
tin stress fibers. Right: merged im-
ages. Scale bars, 50 m.
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filtering bleb site is mainly mediated by HTF proliferation,
migration, and contraction.28–30 Fibroblasts, including HTFs,21
are stimulated by growth factors to differentiate into myofibro-
blasts both in vitro31–33 and in vivo.34 Myofibroblasts are re-
sponsible for fibrosis via increased ECM synthesis, for granula-
tion tissue formation, and wound contraction.35,36
The use of antimetabolites has been one of the most impor-
tant developments in glaucoma surgery.37,38 However, antime-
tabolite treatment can result in several postoperative bleb-
related problems.1,39,40 Therefore, alternative anti-scarring
agents that do not cause extensive tissue damage are needed.
In the present study, a specific ROCK inhibitor, Y-27632,
induced profound changes in cultured HTFs without signifi-
cant toxicity or inhibition of HTF proliferation. In addition,
topical instillation of Y-27632 was highly effective in reducing
scar tissue formation in a rabbit model of glaucoma filtration
surgery.
Our in vitro results revealed that exposure to Y-27632
enhanced adhesiveness of cells to the ECM. This finding cor-
relates well with our previous report on TM cells.19 The actin
cytoskeleton is known to interact with integrins to regulate cell
shape and adhesiveness of cells to the ECM. Y-27632 report-
edly promotes integrin adhesion in cultured THP-1 mono-
cytes.41 Our immunocytochemical investigation in the present
study documented redistribution of focal adhesions in the cell
periphery (Fig. 4B). This increased adhesiveness of cells to the
ECM may be related to alterations in cell shape and redistribu-
tion of focal adhesions to the cell periphery.
LPA, a bioactive lipid growth factor that is present in aque-
ous humor, regulates various cellular events.42 LPA, associated
with activation of the Rho, induces very strong actin fibers and
focal adhesions in various kinds of cells. A previous study of
myofibroblasts demonstrated that LPA and serum, as well as
TGF-, could activate myofibroblast differentiation.43,44 which
is supposedly one of the most potent stimulators of HTFs.29
After glaucoma filtration surgery, HTFs are likely to be exposed
to LPA via serum and/or plasma, because the blood–aqueous
humor barrier breaks down, and circulating aqueous humor
bathes the wound site.45 Y-27632 has been reported to inhibit
LPA-promoted myofibroblast contraction in the collagen lattice
model, which suggests that contraction depends on activation
of the Rho.46–48 In the present study, we investigated LPA-
induced -SMA expression in HTFs to analyze the direct role of
the Rho signaling pathway in these cells. Treatment with
Y-27632 reduced LPA-induced -SMA expression in HTFs,
which suggests that Y-27632 functions as a potent antiscarring
agent via inhibition of transdifferentiation of HTFs into myofi-
broblasts.
FIGURE 3. Effects of Y-27632 on HTF-mediated collagen gel contrac-
tion. (A) Collagen gels were incubated without (Control) or with
Y-27632 (1, 10, or 100 M) for up to 96 hours. (B) The extent of
contraction of collagen gels mediated by HTFs was expressed as the
decrease in gel diameter compared with the initial diameter. Changes
in diameters of collagen gels in the absence (control) or presence of
Y-27632 at 1, 10, or 100 M were measured. Data are shown as the
mean  SEM (n 4). P  0.001 versus control. Compared with the
control, Y-27632 caused statistically significant, concentration-depen-
dent inhibition of HTF-mediated collagen gel contraction (P  0.001).
FIGURE 4. Effects of Y-27632 on cell motility activities of HTFs. (A)
Confluent cultures were scraped with a yellow pipette tip to create a
cell-free linear wound. Medium was replaced with fresh medium with-
out (control) or with Y-27632 (1, 10, or 100 M). After 9 hours,
migration of cells into the wound area was photographed. Dotted
lines: edges of the migrated cells. (B) Distances between edges of
migrated cells were measured and are shown as the mean  SEM (n 
6); the distance before treatment was set at 100%. *P  0.05, †P 
0.001 versus control.
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Gel contraction experiments using three-dimensional cul-
tures of HTFs embedded in collagen type I gels revealed that
addition of Y-27632 decreased contraction of gels. This result
suggests reduced cell contractility and/or altered interaction
between HTFs and collagen type I. Y-27632 treatment in-
creased cell adhesion to collagen type I, and so the change in
gel contraction is thought to be due to the relaxation of the
HTFs induced by Y-27632.
Our results indicate that administration of Y-27632 en-
hanced the motility of the HTFs, which is in agreement with
the idea that stabilization of actin stress fibers limits cell move-
ment. We have reported that Y-27632 enhances motility of
cultured TM cells.19 In the same study, we demonstrated re-
duced levels of phosphorylated LIM kinase 2 and cofilin, which
is one of the targets downstream of Rho signaling pathways. A
previous report from other laboratories showed that constitu-
tively active RhoAV14 significantly inhibited wound closure
and that incubation with Y-27632 promotes wound healing.20
As shown by others49,50 and according to findings in the
present study, inhibition of formation of stress fibers and focal
adhesions via Y-27632 improves cell migration during wound
healing. Several candidate antiscarring agents, such as alky-
lphosphocholines and p38 inhibitors, are also reported to in-
hibit HTF proliferation and contraction.3,4 Although alkylphos-
phocholines are reported to inhibit migration of HTFs,3 the
main effect of p38 inhibitors is supposed to be an inhibition of
transdifferentiation of HTFs into myofibroblasts.4 In contrast, it
is interesting that we found that Y-27632 not only increased
migration but also inhibited cell contraction and transdifferen-
tiation of HTFs into myofibroblasts. These findings, taken to-
gether, suggest that inhibition of migration may not be neces-
sary for antiscarring effects when associated with decreased
myofibroblast transdifferentiation and inhibited cell contrac-
tion. However, further studies are needed to elucidate the
association of migration and scar formation after Y-27632 treat-
ment.
In an animal model of filtration surgery, obstruction of the
sclerostomy site from excessive ECM deposition and contrac-
FIGURE 5. Postoperative IOP, bleb
features, and bleb scores. (A) Repre-
sentative postoperative photographs
show surviving conjunctival blebs in
the Y-27632-treated group that re-
mained diffusely elevated (top). A flat,
scarred, vascularized bleb, formed af-
ter vehicle treatment, is an example of
a bleb that did not survive (bottom).
Arrows: edges of the blebs. (B) Post-
operative IOP changes in the two
groups showed significance between
the Y-27632-treated group and the ve-
hicle-treated group 7 days (P  0.05)
after surgery. (C) Bleb scores for rabbit
eyes treated with Y-27632 or vehicle.
The mean  SEM for six eyes for each
treatment is shown for 7 postoperative
days. Y-27632-treated eyes exhibited
significantly higher bleb scores com-
pared with the control during the 7
days (P  0.001). Y-27632-treated eyes
exhibited significantly higher bleb
scores compared with the control
from days 4 to 7. (*P  0.05, †P 
0.001, ‡P  0.005 versus control.)
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tion due to transdifferentiation of fibroblasts into myofibro-
blasts, which is characterized by synthesis of -SMA, have been
reported.51,52 In our present study, histologic analysis of rabbit
tissues showed that topical instillation of Y-27632 significantly
reduced subconjunctival collagen deposition compared with
controls. Y-27632 also significantly reduced the population of
cells expressing -SMA, which indicates inhibition of myofibro-
blast transdifferentiation in vivo. These observations are in
good agreement with the present in vitro data that Y-27632
significantly reduced -SMA expression in HTFs, suggesting
that beneficial effects of Y-27632 in glaucoma surgery may be
mediated by reduced cell contraction and inhibition of trans-
differentiation of fibroblasts.
Previously, we have reported the significant IOP-lowering
effects of ROCK inhibitors and have shown the possibilities for
clinical use.18,53 We have already conducted a phase I clinical
trial for the ROCK inhibitor as an IOP-lowering agent and have
demonstrated its safety and effectiveness.54 The present study
showed that ROCK inhibitors may have beneficial effects, not
only for IOP-lowering but also for bleb formation after filtering
surgery. However, further studies are needed to determine the
optimal dosage for antiscarring effects. In addition, no direct
comparisons were made with effects of MMC. Therefore, we
are currently performing a comparison of surgical outcomes
for use of Y-27632 and MMC.
In conclusion, our results indicate that Y-27632, a selective
ROCK inhibitor, effectively reduced subconjunctival scarring
after experimental glaucoma filtration surgery. Y-27632 was
safe and well tolerated in this model. Further study is needed to
determine whether inhibition of the ROCK/ROK family can
lead to development of an alternative, more physiological
agent to protect against postoperative scarring.
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